Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenström macroglobulinemia: Clinical and biologic results of a phase II multicenter study

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2233-2238

  Laszlo, Daniele ^a   Andreola, Giovanna ^a   Rigacci, Luigi ^a   Fabbri, Alberto ^a   Rabascio, Cristina ^a   Mancuso, Patrizia ^a   Pruneri, Giancarlo ^a   Radice, Davide ^a   Pinto, Antonello ^a   Frigeri, Ferdinando ^a   Calabrese, Liliana ^a   Billio, Atto ^a   Bertolini, Francesco ^a   Martinelli, Giovanni ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; NUCLEOSIDE TRANSPORTER; PROTEIN KINASE ZAP 70; RITUXIMAB; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CIF NUCLEOSIDE TRANSPORTER; MONOCLONAL ANTIBODY; ZAP70 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BRONCHOSPASM; CARDIOTOXICITY; CLINICAL ARTICLE; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNOPHENOTYPING; INFECTION; MALE; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENETICS; GENOTYPE; IMMUNOLOGY; ITALY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; IMMUNOPHENOTYPING; INJECTIONS, SUBCUTANEOUS; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77952300539     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6315     Document Type: Article

References (27)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000 (Pubitemid 30036355)
2. Johnson SA, Birchall J, Luckie C, et al: Haemato-Oncology Task Force of the British Committee for Standards in Haematology: Guidelines on the management of Waldenstrom macroglobulinaemia. Br J Haematol 132:683-697, 2006
3. Treon SP, Gertz MA, Dimopoulos M, et al: Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood 107:3442-3446, 2006
4. Dimopoulos MA, Gertz MA, Kastritis E, et al: Update on treatment recommendation from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 27:120-126, 2009
5. Johnson SA, Owen RG, Oscier DG, et al: Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. Clin Lymphoma 5:294-297, 2005 (Pubitemid 40614247)
6. Leblond V, Levy V, Maloisel F, et al: Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide- doxorubicinprednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98:2640-2644, 2001
7. Hellmann A, Lewandowski K, Zaucha JM, et al: Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol 63:35-41, 1999 (Pubitemid 29305615)
8. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30:243-247, 2003 (Pubitemid 36506318)
9. Dimopoulos MA, Kantarjian H, Estey E, et al: Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118:195-198, 1993 (Pubitemid 23034805)
10. Dimopoulos MA, Kantarjian H, Wela D, et al: Primary therapy of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-2698, 1994
11. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al: Cladribine (2-CdA) given as subcutaneous bolus injections is active in pre-treated Waldenstrom's macroglobulinemia. Br J Haematol 99:358-363, 1997 (Pubitemid 27497567)
12. Hanson CA, Kurtin PJ, Katzmann JA, et al: Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood 94:3889-3896, 1999
13. Rabascio C, Laszlo D, Andreola G, et al: Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2′-deoxyadenosine (2-CdA) and Rituximab. Leuk Res [epub ahead of print on July 31, 2009]
14. Morel P, Duhamel A, Gobbi P, et al: International prognostic scoring system for Waldenstrom's Macroglobulinemia. Blood 113:4163-4170, 2009
15. Kimbly E: Treatment of Waldenstrom's macroglobulinemia. Haematologica 2:294-301, 2008
16. Treon S, Ioakimidis L, Soumerai J, et al: Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 27:3830-3835, 2009
17. Bertazzoni P, Rabascio C, Calabrese L, et al: Rituximab and 2-Cda activity in CLL/SLL patients: An update of pharmacogenomics and clinical results. Blood 112:11, 2008 (abstr 3171)
18. Treon SP, Emmanouilides C, Kimby E, et al: Waldenstrom's Macroglobulinemia Clinical Trials Group: Extended Rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 16:132-138, 2005 (Pubitemid 40124490)
19. Tedeschi A, Miqueleiz S, Ricci F, et al: Fludarabine, cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia: An effective regimen requiring a new category of response criteria and a delayed assessment of results. Haematologica 92:226, 2007
20. Liliemark J, Martinsson U, Cavallin-Stahl E, et al: Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 30:573-581, 1998 (Pubitemid 28393691)
21. Leleu XL, Soumerai J, Roccaro A, et al: Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 27:250-255, 2009
22. World Health Organization: WHO classification of Tumours of Haematopoetic and Lymphoid Tissue (ed 4). Geneva, Switzerland, World Health Organization, 2008
23. Konoplev S, Medeiros LJ, Bueso-Ramos CE, et al: Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol 124:414-420, 2005 (Pubitemid 41232928)
24. Hunter ZR, Branagan AR, Manning R, et al: Cd5, CD10 and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 5:246-249, 2005
25. Damaraju VL, Damaraju S, Young JD, et al: Nucleoside anticancer drugs: The role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536, 2003 (Pubitemid 37487174)
26. Pennycooke M, Chaudary N, Shuralyova I, et al: Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280:951-959, 2001 (Pubitemid 32924526)
27. Pastor-Anglada M, Molina-Arcas M, Casado FJ, et al: Nucleoside transporters in chronic lymphocytic leukemia. Leukemia 18:385-393, 2004 (Pubitemid 38425849)